


Maxacalcitol-d₆

Cat. No.:	HY-15329
Molecular Formula:	C ₂₆ H ₃₆ D ₆ O ₄
Molecular Weight:	424.65
Target:	VD/VDR
Pathway:	Vitamin D Related/Nuclear Receptor
Storage:	4°C, protect from light, stored under nitrogen * The compound is unstable in solutions, freshly prepared is recommended.



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (235.49 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.3549 mL	11.7744 mL	23.5488 mL
				5 mM	0.4710 mL	2.3549 mL	4.7098 mL
10 mM				0.2355 mL	1.1774 mL	2.3549 mL	
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.89 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.89 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.89 mM); Clear solution						

BIOLOGICAL ACTIVITY

Description	Maxacalcitol-d ₆ is the deuterated form of Maxacalcitol (22-Oxacalcitriol), which is a non-calcemic vitamin D3 analog and VDR ligand of VDR-like receptors.
-------------	--

REFERENCES

[1]. Monier-Faugere et al 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. *Kidney Int.* (1999)55 821.

[2]. Barroga et al Inhibitory effects of 22-oxa-calcitriol and all-trans retinoic acid on the growth of a canine osteosarcoma derived cell-line in vivo and its pulmonary metastasis in vivo. *Res.Vet.Sci.* (2000)68 79.

[3]. Inoue K, Matsui I, Hamano T, Fujii N, Shimomura A, Nakano C, Kusunoki Y, Takabatake Y, Hirata M, Nishiyama A, Tsubakihara Y, Isaka Y, Rakugi H. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3. *Lab Invest.* 2012 Aug 27.

[4]. Karashima T, Hashikawa K, Ono F, Eguchi H, Hamada T, Ishii N, Dainichi T, Yasumoto S, Tsuruta D, Hashimoto T. Successful Treatment of Bowen's Disease with Topical Maxacalcitol. *Acta Derm Venereol.* 2012 Jan 26.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA